Business
Avacta Life Sciences Exhibits Affimers at PEGS
Avacta Life Sciences Exhibits Affimers at PEGS.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 1587I Avacta Group PLC 28 May 2014 \n \n\n \nAvacta Group plc\n(\"Avacta\" or the \"Group\")\n \nAvacta Life Sciences Exhibits Affimers at Global Protein Engineering Summit\nAffimer technology well received at largest international protein engineering gathering\n \nAvacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Avacta Life Sciences exhibited recently at the Global Protein Engineering Summit (\"PEGS\") where it presented its Affimer technology. \n \nPEGS is considered to be the essential protein engineering meeting where commercial and academic progress in protein engineering is showcased and this year it attracted over 1800 delegates from across the globe to Boston. Avacta Life Sciences presented its Affimer technology for the first time at a PEGS meeting with technical exhibits and a presentation by the CSO, Paul Ko Ferrigno, entitled \"Biological Recognition: Beyond the Antibody.\"*\n \nThe exhibition booth was busy with over 80 delegates talking to the Company management team over the four days of the summit. The feedback on the Affimer technology was very positive, in particular, the short development times and excellent stability were highlighted by delegates as key advantages of Affimers over antibodies. There was also a strong interest in Affimers from the management of companies developing biological therapeutics who were keen to learn more about the potential of Affimers as novel therapeutics. \n \nIn addition, several companies were interested in the use of Affimers as an alternative to antibodies in diagnostic devices, mainly because they could generate binders against new biomarkers much more quickly and evaluate them in higher numbers. \n \nThe benefits of Affimer microarrays for biomarker discovery also resonated with diagnostic developers who appreciated the advantage of being able to evaluate significantly larger numbers of potential biomarkers more cost and time effectively than by mass spectrometry. The potential of the arrays for multiplexed solutions for clinical diagnosis and monitoring during drug trials was also something that generated interest amongst those delegates.\n \nMatt Johnson, Chief Technical Officer of Avacta Life Sciences c...